Physician profile
Zhao Liu
NPI 1942356365
$1,594.15
in general payments reported to CMS, 2019-2025
18 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $11.13 · 2021: $186 · 2022: $205 · 2023: $351 · 2024: $243 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000 · Education: $23.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.91 |
| Education | $23.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $293.02 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $201.31 | 2019-2024 | Rayaldee |
| Amgen INC. | $191.49 | 2024-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $165.55 | 2021-2024 | |
| Fresenius USA Marketing, INC. | $107.56 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Calliditas Therapeutics US INC. | $93.26 | 2023-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $81.01 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $80.32 | 2019-2023 | Farxiga |
| Vifor Pharma, INC. | $77.92 | 2021-2024 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $72.08 | 2021-2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $66.91 | 2024-2025 | Acthar |
| Travere Therapeutics, INC. | $43.00 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $27.48 | 2023 | Givlaari |
| Aurinia Pharma U.S., INC. | $22.75 | 2023 | Lupkynis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.58 | 2023 | Jynarque |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $19.02 | 2022 | |
| Akebia Therapeutics INC | $17.66 | 2019 | |
| Emd Serono, INC. | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhao Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.